Aflac director Joseph L. Moskowitz sells $107,630 in stock

Published 11/03/2025, 14:30
Aflac director Joseph L. Moskowitz sells $107,630 in stock

Joseph L. Moskowitz, a director at Aflac Inc . (NYSE:AFL), recently sold 1,000 shares of the company’s common stock. The transaction, which took place on March 7, was conducted at a price of $107.63 per share, amounting to a total sale value of $107,630. Following this sale, Moskowitz holds 25,393 shares in the insurance company, which currently has a market capitalization of $58.35 billion and trades at an attractive P/E ratio of 11. According to InvestingPro analysis, Aflac’s stock is currently trading near its Fair Value, with the company maintaining a "GREAT" financial health score.

The sale was executed under a pre-established Rule 10b5-1 trading plan, which Moskowitz adopted on December 4, 2024. These plans allow company insiders to set up a predetermined schedule for buying or selling stock, helping to avoid any potential accusations of insider trading. InvestingPro data reveals that Aflac has maintained dividend payments for 53 consecutive years, with a current yield of 2.17%. Subscribers can access 8 additional ProTips and comprehensive financial metrics in the Pro Research Report, offering deeper insights into Aflac’s financial strength and market position.

In other recent news, AFLAC Incorporated reported its fourth-quarter earnings for 2024, which revealed an earnings per share (EPS) of $1.56, falling short of the forecasted $1.62. Despite this miss, the company reported strong revenue figures, totaling $5.4 billion, which exceeded the anticipated $4.23 billion. Barclays (LON:BARC) responded to the earnings report by lowering its price target for AFLAC from $98.00 to $95.00, maintaining an Underweight rating due to concerns over the company’s new guidance and potential margin pressures in Japan.

On a more positive note, CFRA increased its price target for AFLAC to $112, maintaining a Buy rating, reflecting confidence in the company’s valuation and financial performance. Piper Sandler also maintained an Overweight rating on AFLAC, highlighting the company’s strategy to launch a new cancer insurance product in April and its lower exposure to variable interest entities as positive factors. Additionally, Piper Sandler mentioned potential internal reinsurance transactions in Bermuda as a strategic move to watch.

AFLAC’s U.S. segment saw growth in net earned premiums and an increase in persistency, although sales in the U.S. experienced a decline. Meanwhile, in Japan, the company faced a decrease in net earned premiums due to reinsurance transactions and policies reaching paid-up status, though adjusted net investment income in Japan increased. The company’s board declared a first-quarter dividend of $0.58 per share, continuing its commitment to shareholder returns through dividends and share repurchases.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.